Skip to main content
. 2020 Mar 17;13(4):100755. doi: 10.1016/j.tranon.2020.100755

Figure 2.

Figure 2

Kaplan-Meier plot of overall survival probability. Overall survival (OS) for recurrent GBM patients treated with ChemoID-guided responsive drugs. Patients receiving ChemoID responsive drugs had a median survival of 13.3 months. Twelve months survival probability was 57% (95% CI: 28% to 78%), based upon Kaplan–Meier estimates.